Phase 2
N=52
MRX-800: A Long-Term Safety Study of Maralixibat in the Treatment of Cholestatic Liver Disease in Subjects Who Previously Participated in a Maralixibat Study
Cholestatic Liver Disease
Bottom Line
View on ClinicalTrials.gov: NCT04168385 ↗Enrolled (actual)
52
Serious AEs
25.0%
Results posted
Dec 2025
Primary outcome: Primary: Incidence of Treatment-Emergent Adverse Events — 36; 12; 9; 4 Participants
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 2
- Interventions
- Maralixibat (Drug)
- Age
- Pediatric, Adult, Older Adult · 0+ yrs
- Sex
- All
- Sponsor
- Mirum Pharmaceuticals, Inc.
- Primary completion
- Sep 2024
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Incidence of Treatment-Emergent Adverse Events |
36; 12; 9; 4; 10; 3 | — |
| SECONDARY Long-Term Effect on Pruritus |
-0.4; -0.3 | — |
| SECONDARY Long-Term Effect on Serum Bile Acid Levels |
-15.948; -82.647; -59.994 | — |
Summary
Evaluate the long-term safety of maralixibat (MRX) in subjects with cholestatic liver disease including, but not limited to, Alagille Syndrome (ALGS), Progressive Familial Intrahepatic Cholestasis (PFIC) and Biliary Atresia.
Eligibility Criteria
Inclusion Criteria Subjects will need to meet all criteria below to be considered eligible for the study.
- Provide informed consent and assent (as applicable) per the Institutional Review Board/Ethics Committee (IRB/EC).
- Previously participated in a maralixibat study and with approval of the Medical Monitor. Previous participation is defined as:
- Having completed the EOT Visit, for subjects coming from the maralixibat Phase 2 studies.
- Having completed the entire duration of the study (i.e., core and extension, if applicable), for subjects coming from the maralixibat Phase 3 studies.
- At least 1 year of age
- Males, and females of non-childbearing potential. Males and non-pregnant, non-lactating females of childbearing potential who are sexually active must agree to use acceptable contraception during the study and 30 days following the last dose of the study medication. Females of childbearing potential must have a negative pregnancy test.
- Caregivers (and/or age appropriate subjects) must have access to email or phone for scheduled remote visits if applicable.
- Subject and caregiver willingness to comply with all study visits and requirements.
Exclusion Criteria
A subject will be excluded from the study if any of the following exclusion criteria are met:
- Experienced an AE or SAE related to maralixibat during the lead-in protocol that led to permanent discontinuation of the subject from maralixibat.
- Any conditions or abnormalities (including laboratory abnormalities) which, in the opinion of the Investigator or Medical Monitor may compromise the safety of the subject or interfere with the subject participating in or completing the study.
- History of non-adherence to medical regimens, unreliability, medical condition, mental instability or cognitive impairment that, in the opinion of the Investigator or Sponsor medical monitor, could compromise the validity of informed consent, compromise the safety of the subject, or lead to non-adherence with the study protocol or inability to conduct the study procedures.
Data sourced from ClinicalTrials.gov (NCT04168385). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.